Impact of chemotherapeutic agents on the immunostimulatory properties of human 6-sulfo LacNAc+ (slan) dendritic cells

International Journal of Cancer

Volumn 132, Issue 6, 2013, Pages 1351-1359

  Wehner, Rebekka ^a   Bitterlich, Anna ^a   Meyer, Nicole ^a   Kloß, Anja ^a   Schäkel, Knut ^b   Bachmann, Michael ^a,c   Schmitz, Marc ^a,c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

chemotherapy; dendritic cells; tumor immunology

Indexed keywords

CD45RA ANTIGEN; DOXORUBICIN; INTERLEUKIN 12; INTERLEUKIN 6; METHOTREXATE; MITOMYCIN; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE;

6 SULFO LACNAC+ DENDRITIC CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; HELPER CELL; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

AMINO SUGARS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYTOKINES; DENDRITIC CELLS; DOXORUBICIN; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; VINBLASTINE;

EID: 84872966087     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27786     Document Type: Article

References (30)

1. Emens LA,. Chemoimmunotherapy. Cancer J 2010; 16: 295-303.
2. Gabrilovich DI,. Combination of chemotherapy and immunotherapy for cancer: A paradigm revisited. Lancet Oncol 2007; 8: 2-3. (Pubitemid 44943085)
3. McDonnell AM, Nowak AK, Lake RA,. Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol 2011; 33: 353-67.
4. Zitvogel L, Kepp O, Kroemer G,. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8: 151-60.
5. Tesniere A, Apetoh L, Ghiringhelli F, et al. Immunogenic cancer cell death: A key-lock paradigm. Curr Opin Immunol 2008; 20: 504-11.
6. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61. (Pubitemid 46067386)
7. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9. (Pubitemid 47517504)
8. Ramakrishnan R, Assudani D, Nagaraj S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120: 1111-24.
9. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-8. (Pubitemid 46348738)
10. Lutsiak ME, Semnani RT, De PR, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-8. (Pubitemid 40446280)
11. Le HK, Graham L, Cha E, et al. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9: 900-9.
12. Steinman RM, Banchereau J,. Taking dendritic cells into medicine. Nature 2007; 449: 419-26. (Pubitemid 47509552)
13. Palucka K, Banchereau J,. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-77.
14. Wehner R, Dietze K, Bachmann M, et al. The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun 2011; 3: 258-63.
15. Moretta A,. The dialogue between human natural killer cells and dendritic cells. Curr Opin Immunol 2005; 17: 306-11. (Pubitemid 40692667)
16. Shurin GV, Tourkova IL, Kaneno R, et al. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 2009; 183: 137-44.
17. Pfannenstiel LW, Lam SS, Emens LA, et al. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 2010; 263: 79-87.
18. Tanaka H, Matsushima H, Mizumoto N, et al. Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells. Cancer Res 2009; 69: 6978-86.
19. Kaneno R, Shurin GV, Tourkova IL, et al. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med 2009; 7: 58.
20. Chao D, Bahl P, Houlbrook S, et al. Human cultured dendritic cells show differential sensitivity to chemotherapy agents as assessed by the MTS assay. Br J Cancer 1999; 81: 1280-4.
21. Nakashima H, Tasaki A, Kubo M, et al. Effects of docetaxel on antigen presentation-related functions of human monocyte-derived dendritic cells. Cancer Chemother Pharmacol 2005; 55: 479-87. (Pubitemid 40568979)
22. Schäkel K, Mayer E, Federle C, et al. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol 1998; 28: 4084-93. (Pubitemid 28558638)
23. Schäkel K, Kannagi R, Kniep B, et al. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002; 17: 289-301. (Pubitemid 35279550)
24. Schäkel K, von Kietzell M, Hänsel A, et al. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 2006; 24: 767-77. (Pubitemid 43884896)
25. Schmitz M, Zhao S, Schäkel K, et al. Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. Blood 2002; 100: 1502-4. (Pubitemid 34864314)
26. Schmitz M, Zhao S, Deuse Y, et al. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol 2005; 174: 4127-34. (Pubitemid 40395990)
27. Marin-Esteban V, Charron D, Gelin C, et al. Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation. J Immunother 2010; 33: 364-70.
28. John J, Ismail M, Riley C, et al. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol 2010; 11: 14.
29. Straube C, Wehner R, Wendisch M, et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 2007; 21: 1464-71. (Pubitemid 46965288)
30. Wehner R, Löbel B, Bornhäuser M, et al. Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells. Int J Cancer 2009; 124: 358-66.